Assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitors

Goal. To assess the effect of topical treatment of atopic dermatitis patients with the 0.1% tacrolimus ointment on the itching intensity and skin expression level of growth factor proteins affecting the intensity of cutaneous innervation. Materials and methods. Fifteen patients suffering from atopic...

Full description

Bibliographic Details
Main Authors: V. V. Chikin, V. A. Smolyannikova, D. V. Proshutinskaya, M. A. Nefedova
Format: Article
Language:Russian
Published: State Scientific Center of Dermatovenereology and Cosmetology 2017-08-01
Series:Vestnik Dermatologii i Venerologii
Subjects:
Online Access:https://www.vestnikdv.ru/jour/article/view/238
id doaj-04a8046aff4044849a8d5cc2089c2c3a
record_format Article
spelling doaj-04a8046aff4044849a8d5cc2089c2c3a2020-11-25T02:37:30ZrusState Scientific Center of Dermatovenereology and CosmetologyVestnik Dermatologii i Venerologii0042-46092313-62942017-08-0103465510.25208/0042-4609-2016-0-3-46-55237Assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitorsV. V. Chikin0V. A. Smolyannikova1D. V. Proshutinskaya2M. A. Nefedova3State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian FederationI. M. Sechenov First Moscow State Medical UniversityState Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian FederationState Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian FederationGoal. To assess the effect of topical treatment of atopic dermatitis patients with the 0.1% tacrolimus ointment on the itching intensity and skin expression level of growth factor proteins affecting the intensity of cutaneous innervation. Materials and methods. Fifteen patients suffering from atopic dermatitis underwent treatment with the 0.1% tacrolimus ointment. The SCORAD index was calculated to assess the severity of clinical manifestations. The itching intensity was assessed using a visual analogue scale. The skin expression of nerve growth factors, amphiregulin, semaphorin 3A and PGP9.5 protein (a nerve fiber marker) was assessed by the indirect immunofluorescence method. Results. An increased expression of the nerve growth factor and reduced semaphorin 3A expression levels were noted in the patients’ epidermis; there was an increase in the quantity, mean length and fluorescence intensity of PGP9.5+ nerve fibers. As a result of the treatment, the disease severity and itching intensity were reduced, the nerve growth factor expression level was reduced while semaphorin 3A expression level increased in the epidermis, and the mean length and fluorescence intensity of PGP9.5+ nerve fibers was also reduced. A positive correlation among the itching intensity and nerve growth factor expression level, quantity and mean length of PGP9.5+ nerve fibers in the epidermis was revealed, and negative correlation between the itching intensity and semaphorin 3A expression level in the epidermis was established. Conclusion. Topical treatment with the 0.1% Tacrolimus ointment reduces the itching intensity in atopic dermatitis patients, which is related to the therapy-mediated reduction in the epidermis innervation level, decreased expression of epidermal nerve growth factor and increased semaphorin 3A expression level.https://www.vestnikdv.ru/jour/article/view/238атопический дерматитзудтакролимусфактор роста нервовсемафорин-3аpgp9.5--нервные волокна эпидермисаatopic dermatitisitchingtacrolimusnerve growth factorsemaphorin 3apgp9.5-nerve fibers in the epidermis
collection DOAJ
language Russian
format Article
sources DOAJ
author V. V. Chikin
V. A. Smolyannikova
D. V. Proshutinskaya
M. A. Nefedova
spellingShingle V. V. Chikin
V. A. Smolyannikova
D. V. Proshutinskaya
M. A. Nefedova
Assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitors
Vestnik Dermatologii i Venerologii
атопический дерматит
зуд
такролимус
фактор роста нервов
семафорин-3а
pgp9.5--нервные волокна эпидермиса
atopic dermatitis
itching
tacrolimus
nerve growth factor
semaphorin 3a
pgp9.5-nerve fibers in the epidermis
author_facet V. V. Chikin
V. A. Smolyannikova
D. V. Proshutinskaya
M. A. Nefedova
author_sort V. V. Chikin
title Assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitors
title_short Assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitors
title_full Assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitors
title_fullStr Assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitors
title_full_unstemmed Assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitors
title_sort assessing the itching intensity using visual analogue scales in atopic dermatitis patients against the background of a therapy with calcineurin inhibitors
publisher State Scientific Center of Dermatovenereology and Cosmetology
series Vestnik Dermatologii i Venerologii
issn 0042-4609
2313-6294
publishDate 2017-08-01
description Goal. To assess the effect of topical treatment of atopic dermatitis patients with the 0.1% tacrolimus ointment on the itching intensity and skin expression level of growth factor proteins affecting the intensity of cutaneous innervation. Materials and methods. Fifteen patients suffering from atopic dermatitis underwent treatment with the 0.1% tacrolimus ointment. The SCORAD index was calculated to assess the severity of clinical manifestations. The itching intensity was assessed using a visual analogue scale. The skin expression of nerve growth factors, amphiregulin, semaphorin 3A and PGP9.5 protein (a nerve fiber marker) was assessed by the indirect immunofluorescence method. Results. An increased expression of the nerve growth factor and reduced semaphorin 3A expression levels were noted in the patients’ epidermis; there was an increase in the quantity, mean length and fluorescence intensity of PGP9.5+ nerve fibers. As a result of the treatment, the disease severity and itching intensity were reduced, the nerve growth factor expression level was reduced while semaphorin 3A expression level increased in the epidermis, and the mean length and fluorescence intensity of PGP9.5+ nerve fibers was also reduced. A positive correlation among the itching intensity and nerve growth factor expression level, quantity and mean length of PGP9.5+ nerve fibers in the epidermis was revealed, and negative correlation between the itching intensity and semaphorin 3A expression level in the epidermis was established. Conclusion. Topical treatment with the 0.1% Tacrolimus ointment reduces the itching intensity in atopic dermatitis patients, which is related to the therapy-mediated reduction in the epidermis innervation level, decreased expression of epidermal nerve growth factor and increased semaphorin 3A expression level.
topic атопический дерматит
зуд
такролимус
фактор роста нервов
семафорин-3а
pgp9.5--нервные волокна эпидермиса
atopic dermatitis
itching
tacrolimus
nerve growth factor
semaphorin 3a
pgp9.5-nerve fibers in the epidermis
url https://www.vestnikdv.ru/jour/article/view/238
work_keys_str_mv AT vvchikin assessingtheitchingintensityusingvisualanaloguescalesinatopicdermatitispatientsagainstthebackgroundofatherapywithcalcineurininhibitors
AT vasmolyannikova assessingtheitchingintensityusingvisualanaloguescalesinatopicdermatitispatientsagainstthebackgroundofatherapywithcalcineurininhibitors
AT dvproshutinskaya assessingtheitchingintensityusingvisualanaloguescalesinatopicdermatitispatientsagainstthebackgroundofatherapywithcalcineurininhibitors
AT manefedova assessingtheitchingintensityusingvisualanaloguescalesinatopicdermatitispatientsagainstthebackgroundofatherapywithcalcineurininhibitors
_version_ 1724795170075967488